BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Ciaula A, Wang DQ, Wang HH, Bonfrate L, Portincasa P. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2010;39:245-64, viii-ix. [PMID: 20478485 DOI: 10.1016/j.gtc.2010.02.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Di Ciaula A, Wang DQ, Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert Rev Gastroenterol Hepatol 2019;13:157-71. [PMID: 30791781 DOI: 10.1080/17474124.2019.1549988] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Rong ZH, Chen HY, Wang XX, Wang ZY, Xian GZ, Ma BZ, Qin CK, Zhang ZH. Effects of sphincter of Oddi motility on the formation of cholesterol gallstones. World J Gastroenterol 2016; 22(24): 5540-5547 [PMID: 27350732 DOI: 10.3748/wjg.v22.i24.5540] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 van Dooren I, Faouzi MEA, Foubert K, Theunis M, Pieters L, Cherrah Y, Apers S. Cholesterol lowering effect in the gall bladder of dogs by a standardized infusion of Herniaria hirsuta L. Journal of Ethnopharmacology 2015;169:69-75. [DOI: 10.1016/j.jep.2015.03.081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
4 Castro-Torres IG, De la O-Arciniega M, Gallegos-Estudillo J, Naranjo-Rodríguez EB, Domínguez-Ortíz MÁ. Raphanus sativus L. var niger as a source of phytochemicals for the prevention of cholesterol gallstones. Phytother Res 2014;28:167-71. [PMID: 23495001 DOI: 10.1002/ptr.4964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yoo KS. [Management of Gallstone]. Korean J Gastroenterol 2018;71:253-9. [PMID: 29791983 DOI: 10.4166/kjg.2018.71.5.253] [Reference Citation Analysis]
6 Cariati A, Piromalli E. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother 2012;13:1223-7. [PMID: 22607008 DOI: 10.1517/14656566.2012.685161] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jeong SU, Lee SK. [Obesity and gallbladder diseases]. Korean J Gastroenterol 2012;59:27-34. [PMID: 22289951 DOI: 10.4166/kjg.2012.59.1.27] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
8 Portincasa P, Di Ciaula A, de Bari O, Garruti G, Palmieri VO, Wang DQ. Management of gallstones and its related complications. Expert Rev Gastroenterol Hepatol 2016;10:93-112. [PMID: 26560258 DOI: 10.1586/17474124.2016.1109445] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
9 Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018;7. [PMID: 30345010 DOI: 10.12688/f1000research.15505.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
10 de Bari O, Wang TY, Liu M, Paik CN, Portincasa P, Wang DQ. Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Ann Hepatol. 2014;13:728-745. [PMID: 25332259 DOI: 10.1016/s1665-2681(19)30975-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
11 de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2012;2012:302847. [PMID: 22132342 DOI: 10.1155/2012/302847] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
12 Castro-Torres IG, Naranjo-Rodríguez EB, Domínguez-Ortíz MÁ, Gallegos-Estudillo J, Saavedra-Vélez MV. Antilithiasic and hypolipidaemic effects of Raphanus sativus L. var. niger on mice fed with a lithogenic diet. J Biomed Biotechnol 2012;2012:161205. [PMID: 23093836 DOI: 10.1155/2012/161205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
13 Cafasso DE, Smith RR. Symptomatic cholelithiasis and functional disorders of the biliary tract. Surg Clin North Am 2014;94:233-56. [PMID: 24679419 DOI: 10.1016/j.suc.2013.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lam R, Zakko A, Petrov JC, Kumar P, Duffy AJ, Muniraj T. Gallbladder Disorders: A Comprehensive Review. Dis Mon 2021;67:101130. [PMID: 33478678 DOI: 10.1016/j.disamonth.2021.101130] [Reference Citation Analysis]
15 Tuncer I, Harman M, Colak Y, Arslan I, Turkdogan MK. Effect of ursodeoxycholic Acid alone and ursodeoxycholic Acid plus domperidone on radiolucent gallstones and gallbladder contractility in humans. Gastroenterol Res Pract 2012;2012:159438. [PMID: 22611378 DOI: 10.1155/2012/159438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Suuronen S, Niskanen L, Paajanen P, Paajanen H. Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009. Scand J Surg 2013;102:158-63. [PMID: 23963029 DOI: 10.1177/1457496913492463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Wang DQ, Neuschwander-tetri BA, Portincasa P. The Biliary System, Second Edition. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2016;8:i-178. [DOI: 10.4199/c00147ed2v01y201611isp071] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wang HH, Li T, Portincasa P, Ford DA, Neuschwander-Tetri BA, Tso P, Wang DQ. New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile. Liver Res 2017;1:42-53. [PMID: 34367715 DOI: 10.1016/j.livres.2017.05.005] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Han T, Lv Y, Wang S, Hu T, Hong H, Fu Z. PPARγ overexpression regulates cholesterol metabolism in human L02 hepatocytes. Journal of Pharmacological Sciences 2019;139:1-8. [DOI: 10.1016/j.jphs.2018.09.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
20 Cariati A, Piromalli E. Ultrastructural basis of the failure of oral dissolution therapy with bile salts and/or statin for cholesterol gallstones. Expert Opinion on Pharmacotherapy 2012;13:1387-8. [DOI: 10.1517/14656566.2012.663550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
21 Tiderington E, Lee SP, Ko CW. Gallstones: new insights into an old story. F1000Res 2016;5:F1000 Faculty Rev-1817. [PMID: 27508070 DOI: 10.12688/f1000research.8874.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ji G, Xu C, Sun H, Liu Q, Hu H, Gu A, Jiang ZY. Organochloride pesticides induced hepatic ABCG5/G8 expression and lipogenesis in Chinese patients with gallstone disease. Oncotarget 2016;7:33689-702. [PMID: 27203212 DOI: 10.18632/oncotarget.9399] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
23 . EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. Journal of Hepatology 2016;65:146-81. [DOI: 10.1016/j.jhep.2016.03.005] [Cited by in Crossref: 181] [Cited by in F6Publishing: 99] [Article Influence: 30.2] [Reference Citation Analysis]
24 Chowdhury AH, Lobo DN. Gallstones. Surgery (Oxford) 2011;29:610-7. [DOI: 10.1016/j.mpsur.2011.09.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Bonfrate L, Wang DQ, Garruti G, Portincasa P. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Practice & Research Clinical Gastroenterology 2014;28:623-35. [DOI: 10.1016/j.bpg.2014.07.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
26 Bonfrate L, Procino G, Wang DQ, Svelto M, Portincasa P. A novel therapeutic effect of statins on nephrogenic diabetes insipidus. J Cell Mol Med 2015;19:265-82. [PMID: 25594563 DOI: 10.1111/jcmm.12422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
27 Brazzelli M, Cruickshank M, Kilonzo M, Ahmed I, Stewart F, McNamee P, Elders A, Fraser C, Avenell A, Ramsay C. Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation. Health Technol Assess 2014;18:1-101, v-vi. [PMID: 25164349 DOI: 10.3310/hta18550] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
28 Bakonyi D, Hummel W. Cloning, expression, and biochemical characterization of a novel NADP+-dependent 7α-hydroxysteroid dehydrogenase from Clostridium difficile and its application for the oxidation of bile acids. Enzyme Microb Technol 2017;99:16-24. [PMID: 28193327 DOI: 10.1016/j.enzmictec.2016.12.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
29 Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther 2012; 3(2): 7-20 [PMID: 22577615 DOI: 10.4292/wjgpt.v3.i2.7] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 45] [Article Influence: 6.2] [Reference Citation Analysis]
30 Takahashi Y, Yamamichi N, Shimamoto T, Mochizuki S, Fujishiro M, Takeuchi C, Sakaguchi Y, Niimi K, Ono S, Kodashima S, Mitsushima T, Koike K. Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. J Gastroenterol 2014;49:882-9. [PMID: 23736795 DOI: 10.1007/s00535-013-0832-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
31 Zhou Q, Hu H, Zhao G, Liu P, Wang Y, Zhang H. Effect and related mechanism of Yinchenhao decoction on mice with lithogenic diet-induced cholelithiasis. Exp Ther Med 2021;21:316. [PMID: 33717259 DOI: 10.3892/etm.2021.9747] [Reference Citation Analysis]
32 Pak M, Lindseth G. Risk Factors for Cholelithiasis. Gastroenterol Nurs. 2016;39:297-309. [PMID: 27467059 DOI: 10.1097/sga.0000000000000235] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
33 Stender S, Frikke-Schmidt R, Benn M, Nordestgaard BG, Tybjærg-Hansen A. Low-density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses. J Hepatol 2013;58:126-33. [PMID: 22922093 DOI: 10.1016/j.jhep.2012.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
34 Mohssen A, Nicola AA, Predeţeanu D, Copcă N. The Uncertain Link Between Gallstone Disease and Colorectal Cancer. Internal Medicine 2021;18:71-81. [DOI: 10.2478/inmed-2021-0168] [Reference Citation Analysis]
35 Lee JK, Kang HW, Kim JH, Lim YJ, Koh M, Lee JH. Effects of Korean red ginseng as an adjuvant to bile acids in medical dissolution therapy for gallstones: a prospective, randomized, controlled, double-blind pilot trial. Food Funct 2013;4:116-20. [DOI: 10.1039/c2fo30196b] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Wang HH, Portincasa P, Liu M, Tso P, Wang DQ. Similarities and differences between biliary sludge and microlithiasis: Their clinical and pathophysiological significances. Liver Res 2018;2:186-99. [PMID: 34367716 DOI: 10.1016/j.livres.2018.10.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Amoako MO, Casella JF, Strouse JJ. High rates of recurrent biliary tract obstruction in children with sickle cell disease. Pediatr Blood Cancer 2013;60:650-2. [PMID: 23255346 DOI: 10.1002/pbc.24413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Chiu HF, Chen CC, Kuo HW, Lee IM, Wu TN, Yang CY. Statin use and the risk of gallstone disease: a population-based case-control study. Expert Opin Drug Saf 2012;11:369-74. [PMID: 22243480 DOI: 10.1517/14740338.2012.653560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 Döring B, Lütteke T, Geyer J, Petzinger E. The SLC10 carrier family: transport functions and molecular structure. Curr Top Membr. 2012;70:105-168. [PMID: 23177985 DOI: 10.1016/b978-0-12-394316-3.00004-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
40 Kotb MA. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int J Mol Sci 2012;13:8882-914. [PMID: 22942741 DOI: 10.3390/ijms13078882] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
41 Deng J, Ren M, Dai X, Qu D, Yang M, Zhang T, Jiang B. Lysimachia christinae Hance regresses preestablished cholesterol gallstone in mice. J Ethnopharmacol 2015;166:102-8. [PMID: 25794804 DOI: 10.1016/j.jep.2015.03.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]